Cart
sales@molnova.com
Alirocumab
CAS No. 1245916-14-6
Alirocumab( —— )
Catalog No. M22147 CAS No. 1245916-14-6
Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 507 | In Stock |
|
| 5MG | 801 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAlirocumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionAlirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture.
-
DescriptionAlirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture.
-
In VitroCell Viability Assay Cell Line:hiPSC-CMs, hESC-CMs Concentration:0.01, 0.1, 1, 2, 10 μM Incubation Time: 24-72 h Result:Exhibited normal cell viability and did not affect the level of LDH release.
-
In VivoAnimal Model:CETP mice model Dosage:3 or 10 mg/kg Administration:s.c.Result:Decreased total cholesterol dose-dependently.Increased hepatic LDL receptor protein levels but did not affect hepatic cholesterol and TG content.Decreased atherosclerotic lesion size and improved plaque morphology.Animal Model:Rat model (240-280 g) Dosage:10 mg/kg Administration:i.p.Result:Elevated ammonia, total cholesterol, LDL and ox-LDL levels.Decreased plasma levels of total cholesterol, LDL, and oxidative stress markers.
-
Synonyms——
-
PathwayOthers
-
TargetPCSK9
-
RecptorPCSK9
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1245916-14-6
-
Formula Weight146 kDa
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ramanathan A, et al. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes. PLoS One. 2016 Apr 26;11(4):e0154498.
molnova catalog
related products
-
Evolocumab
Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9).
-
O-304
O-304 is a small molecule AMPK activator and PCSK9 modulator, reduces extracellular and secreted PCSK9 levels in human liver cells and reduces PCSK9 plasma levels and total cholesterol levels in obese rats.
-
Alirocumab
Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture.
